A Phase 2 Trial of OPC-64005 for Major Depressive Disorder
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
The objective of the trial is to compare the efficacy of OPC-64005 at 20 mg vs placebo and to
assess the safety and pharmacokinetics of OPC-64005 at 10 and 20 mg in patients with major
depressive disorder (MDD).The primary endpoint is the mean change from baseline in
Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 6 of the double-blind
treatment period in the OPC-64005 20-mg group compared with the placebo group